# A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

> **NCT07260877** · PHASE2 · RECRUITING · sponsor: **Ventus Therapeutics U.S., Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Cutaneous Lupus Erythematosus (CLE)
- Systemic Lupus Erythematosus
- SLE
- SLE (Systemic Lupus)
- CLE

## Interventions

- **DRUG:** VENT-03
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07260877
- **Lead sponsor:** Ventus Therapeutics U.S., Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2026-07
- **Final completion:** 2026-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07260877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07260877, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07260877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*